Leg­is­la­tors call HHS to ac­tion on Xtan­di march-in rights

More than two dozen law­mak­ers are putting re­newed pres­sure on the fed­er­al gov­ern­ment to use its march-in rights to low­er the price of prostate can­cer drug Xtan­di.

The group — led by Sens. Eliz­a­beth War­ren (D-MA) and An­gus King (I-ME), and Rep. Lloyd Doggett (D-TX) — penned a let­ter to HHS Sec­re­tary Xavier Be­cer­ra on Tues­day re­quest­ing a “long over­due” pub­lic hear­ing on a pe­ti­tion to low­er Xtan­di’s price filed by pa­tients more than a year ago. Ear­li­er this month, the pe­ti­tion­ers got word that the NIH is still “cur­rent­ly co­or­di­nat­ing with HHS to re­view and as­sess the in­for­ma­tion,” ac­cord­ing to the let­ter.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER